12 studies found for:    "Adrenal cancer"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Conditions: Breast Cancer;   Lung Cancer;   Renal Cancer;   Adrenal Cancer
Intervention: Drug: FPAC
2 Recruiting Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Conditions: Adrenocortical Carcinoma;   Adrenal Cancer;   ACC
Intervention: Drug: ATR-101
3 Recruiting Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Liver Cancer;   Adrenal Cancer
Intervention: Radiation: stereotactic body radiation therapy
4 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Condition: Adrenocortical Carcinoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
5 Recruiting Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Conditions: Neuroendocrine Neoplasms;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
Intervention:
6 Recruiting Study of Adrenal Gland Tumors
Condition: Adrenal Gland Neoplasm
Intervention:
7 Recruiting Evaluation of Molecular Markers in Adrenal Tumors
Condition: Adrenal Gland Neoplasms
Intervention:
8 Unknown  German Adrenocortical Carcinoma Registry
Condition: Adrenocortical Carcinoma
Intervention:
9 Unknown  Evaluation of Side Effects of Mitotane
Condition: Adrenocortical Carcinoma
Intervention:
10 Completed Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
Condition: Nonresectable Adrenocortical Carcinoma
Intervention: Drug: Iressa (ZD1839)
11 Unknown  Sunitinib in Refractory Adrenocortical Carcinoma
Condition: Adrenocortical Carcinoma
Intervention: Drug: Sunitinib
12 Recruiting Possible New Therapy for Advanced Cancer
Condition: Adrenocortical Carcinoma
Intervention: Drug: IL-13-PE

Indicates status has not been verified in more than two years